Healthcare | September 01, 2021
Metropolis Healthcare opens new testing centre in Thalassery, Kerala
The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests
The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests
It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
Subscribe To Our Newsletter & Stay Updated
